# Cochrane

# Trusted evidence.

# Informed decisions.

# Better health.

# Cochrane Database of Systematic Reviews

# NCT04637438 (Continued)

# Outcomes

# Primary outcome

- Change in endoscopic Rutgeerts score between first and second colonoscopy at 1 year (Rutgeerts endoscopic score ranges from i0 indicating remission to i4 indicating severe postoperative relapse)

# Secondary outcomes

- Safety of FMT (FinFMT-Questionnaire) at 3 and 12 months, and 5 years
- Clinical activity of CD (HBI) at 6 and 12 months, and 5 years
- Histologic activity of CD (modified Global Histological Activity Score) at 1 and 5 years
- Change of microbiota in stool samples and in intestinal biopsies at 6, 12, and 48 weeks, and 5 years
- Participant-reported outcome at 12 and 48 weeks, and 5 years
- Change in inflammatory marker CRP at 6, 12, 24, and 48 weeks, and 5 years
- Need for hospitalization through study completion, at mean of 1 and 5 years
- Need for treatment escalation through study completion, at average of 1 and 5 years
- Fecal calprotectin at 6, 12, 24, and 48 weeks, and 5 years
- Hemoglobin at 6, 12, 24, and 48 weeks, and 5 years

# Starting date

November 2020

# Contact information

Tampere University Hospital

Contact: Elina Jokinen, PhD +3583311611; email: elina.jokinen@pshp.fi

# Notes

# NCT04924270

# Study name

Safety and efficacy of faecal microbiota transplantation in treatment-naïve patients with newly diagnosed chronic inflammatory diseases (FRONT)

# Methods

RCT conducted in Denmark

# Participants

# Inclusion criteria

- New diagnosis of rheumatoid arthritis, reactive arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, gouty arthritis, hidradenitis suppurativa, pulmonary sarcoidosis, CD, or UC
- Treatment-naïve (no current or previous disease-modifying antirheumatic drugs or systemic immunosuppressive drugs including glucocorticoids)
- Presence of treatment indication (no contraindications) and patient acceptance to start first-line treatment in accordance with Danish national guideline for specific diagnosis following baseline visit

# Exclusion criteria

- Celiac disease, food allergy, or severe food intolerance
- Malignancy
- Hepatitis B and C, HIV, HTLV1/2, active tuberculosis, or other serious chronic infections
- Pregnancy or lactation
- Not wishing to participate or not suited for FMT intervention or project evaluation

# Interventions

# Experimental arm

50 g feces diluted in sterile saline (0.9% sodium chloride) and glycerol, blended, centrifuged, and filtered to remove particulate material before transfer to double-layered FMT capsules

# Fecal transplantation for treatment of inflammatory bowel disease (Review)

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.